SCHEMBL23218161

SCHEMBL23218161

CCOC(=O)Cc1ccccc1OCCc1coc2ccc(Br)cc12

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.45
MTNR1A P48039 4/20 0.40
MAPT P10636 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PSMB5 P28074 2/20 0.38
MEN1 O00255 2/20 0.38
POLB P06746 2/20 0.38
KMT2A Q03164 2/20 0.38
MTNR1B P49286 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
PKM P14618 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218949 0.90 TBXAS1 (0.41) TBXAS1MTNR1AMAPTNPSR1PSMB5
SCHEMBL8175604 0.84 MEN1 (0.47) MTNR1AMAPTMEN1POLBKMT2A
SCHEMBL31425808 0.84 MEN1 (0.47) MTNR1AMAPTMEN1POLBKMT2A
SCHEMBL23218059 0.82 CYP4F2 (0.44) MTNR1AMAPTNPSR1MEN1POLB
SCHEMBL23218366 0.82 CFD (0.49) TBXAS1MTNR1APSMB5TP53
SCHEMBL29852811 0.82 MAPT (0.46) TBXAS1MAPTNPSR1MEN1POLB
SCHEMBL23218748 0.82 MAPT (0.46) TBXAS1MAPTNPSR1MEN1POLB
Methylene Chloride SCHEMBL8520941 0.81 MEN1 (0.45) MTNR1AMAPTMEN1POLBKMT2A
SCHEMBL23218697 0.80 MAPT (0.40) MAPTNPSR1MEN1POLBKMT2A
SCHEMBL29852717 0.80 MAPT (0.40) MAPTNPSR1MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed